Hong Kong Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research landscape. Strengthened by its experience in conducting COVID-19 vaccine trials, the global trends towards clinical research in Asia and more…
Hong Kong The Guangzhou production site of HKEX-listed RNA therapeutics biotech Sirnaomics is overseen by pharma industry veteran Edward Wang. Here, Wang explains his contribution to the development of good manufacturing practices (GMP) in China and why southern China makes sense as a manufacturing location for a local biotech with global ambitions.…
Hong Kong Executive director & chief strategy officer at HKEX-listed RNA therapeutics biotech Sirnaomics, Dr Dai Xiaochang is no stranger to Hong Kong and mainland China’s pharma and biotech ecosystem, having held leadership roles at Yunnan Walvax , Kunming Baker Norton and the Kunyao Group. He outlines the company’s RNAi therapeutics pipeline…
See our Cookie Privacy Policy Here
